KEY DEADLINES
Abstract Submission Deadline: CLOSED
Early Bird Registration Deadline: CLOSED
Accommodation Deadline: CLOSED
Standard Registration Deadline: CLOSED
The committee are pleased to announce the poster listing is now available. This will continue to be updated as more details are confirmed, please note this is subject to change without notice.
Clinical Sciences
4. Higher rates of hepatitis B surface antigen (HBsAg) loss in the first 12 months of antiretroviral therapy in the setting of HIV-HBV co-infection
Jennifer Audsley, University of Melbourne, Victoria, Australia
15. Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: The REACT study
Joanne Carson, Unsw / The Kirby Institute, NSW, Australia
2. Curing hepatitis C virus (HCV) with direct-acting antiviral (DAA) treatment: adherence and rapid onset of HCV RNA undetectability after 4 weeks of treatment with sofosbuvir/velpatasvir.
Aurelie Freismuth, Gilead Sciences, VIC, Australia
13. Temporal change in etiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients with hepatocellular carcinoma in New South Wales, Australia
Behzad Hajarizadeh, The Kirby Institute, UNSW, NSW, Australia
Community Research
6. Nurses’ experiences using Hepatitis C Point of Care antibody and RNA testing: exploring ways to engage into care people who inject drugs
Kate Allardice, Burnet Institute, VIC, Australia
Epidemiology and Public Health
16. Reach, Teach, Treat, Thrive: The evolution of a hepatitis C model of care.
Tara Crim, Hepatitis ACT, ACT, Australia
7.Outreach and engagement to achieve hepatitis C micro-elimination in Cairns, Australia
Carla Gorton, Cairns Sexual Health Service, QLD, Australia
12.Prevalence of hepatitis B virus amongst refugees, asylum seekers and internally displaced persons in low- and middle-income countries: A systematic review
Caroline Lee, University of New South Wales, James Cook University, Prince of Wales Hospital, NSW, Australia
8. Project SONIC – Service Optimisation in Needle and Syringe Programs with Incentives and Clinical Pathways
Kate Patten, NSW Ministry Of Health, NSW, Australia
9. Enhancing harm reduction services for Aboriginal and Torres Strait Islander people who inject drugs through improved engagement: lessons learned using the CONSIDER Statement
Emily Pegler, The University Of Queensland, QLD, Australia
Health Services and Systems
10. Harm reduction case management model of care – engaging clients to initiate Hepatitis C Treatment
Jenna Hughes, Queensland Injectors Health Network – QuIHN, QLD, Australia
18. Using Local Policy to Drive Change – Increasing Blood Borne Virus Testing
Sarah Smith, Hiv And Related Programs Seslhd, NSW, Australia
11. Finding the balance between instructive and individualised approaches to clinical auditing
Brett Stevens, Ashm, QLD, Australia
Mathematical Modelling
3. Estimating HCV population size and care cascade by 2021 in Australia
Jisoo Amy Kwon, Kirby Institute, NSW, Australia
17. Micro-elimination in Cairns by 2030: A modelling study to demonstrate the impact of Cairns Hep C Free program.
Kelly Maynard, Burnet Institute, VIC, Australia
Social Research
1. Identifying and understanding the needs for hepatitis C (HCV) education to enhance HCV health literacy and HCV care for people in Australian prisons
Yumi Sheehan, The Kirby Institute, UNSW, Australia
Other
19. REACH-B Advice: Embedding learning and co-design to improve tools and support for hepatitis B s100 community prescribers
Isabelle Purcell, Senior Project Officer, NT, Australia
10. Needs Assessment for hepatitis B clinical auditing and/or case finding: Enablers and barriers to a national scoping project.
Skye O’halloran, Ashm, Qld, Australia